# Delenex Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/delenex-therapeutics

- Industry: Biotechnology
- Headquarters: Zurich, Switzerland
- Website: www.delenex.com
- Total disclosed funding: $41M
- Latest round: Series A (Oct 29, 2013)
- Investors on record: 6

## About

Founded in 2009 and based in Zurich, Switzerland,  Delenex Therapeutics AG operates as a biotechnology company. The firm focuses on research and development of therapeutic antibody fragments targeting serious medical diseases.

## Funding rounds

- Series A, Oct 29, 2013, $7.9M — HBM Partners, BioMed Partners, SV Health Investors, Vi Partners, Novo Holdings A/S
- Series A, May 3, 2011, $19M — HBM Partners, BioMed Partners, SV Health Investors, Novo Holdings, Vi Partners
- Series A, Nov 12, 2010, $14M — HBM Partners, BioMed Partners, SV Health Investors, Vi Partners

## Investors

- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series A
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series A
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A
- Vi Partners (https://capitalatlas.ai/funds/vi-partners) — Series A
- Novo Holdings — Series A
- Novo Holdings A/S — Series A